Results 171 to 180 of about 25,067 (205)
Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells. [PDF]
Sci RepSanter FR +10 more
europepmc +1 more source
Cleavage and inactivation of poly(ADP-ribose) polymerase in peripheral blood mononuclear cells of patients with acute respiratory distress syndrome. [PDF]
Respir ResSantos SS +13 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2018
Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. It is rationally designed to act as a competitive inhibitor of NAD+ at the catalytic site of PARP1 and PARP2, both members of the PARP family of enzymes that are central to the repair of DNA single ...
Sylvia, Bochum +2 more
+6 more sources
Olaparib (Lynparza [AstraZeneca, Cambridge, UK], formerly referred to as AZD2281 or KU0059436) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. It is rationally designed to act as a competitive inhibitor of NAD+ at the catalytic site of PARP1 and PARP2, both members of the PARP family of enzymes that are central to the repair of DNA single ...
Sylvia, Bochum +2 more
+6 more sources